In non-human primates (NHP) and rodent models, administration of the anti-oxidant drug Resveratrol to mothers with obesity during pregnancy improves maternal fasting insulin levels and decreases maternal fat mass, in addition to resolving fetal fatty liver, reducing offspring adiposity and improving leptin sensitivity and brown adipose tissue function [78,79]. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.